Radial cheek lines (RCL) may convey an older, potentially less attractive appearance.
To evaluate the effectiveness of hyaluronic acid–based dermal filler VYC-17.5L for correcting RCL.
Fifty-three women (40–65 years) received injections of VYC-17.5L in both cheeks on Day 1 (optional Day 14 touch-up). Effectiveness was evaluated on Day 45 by subject-rated dynamic RCL improvement (Global Aesthetic Improvement Scale [GAIS]; primary end point) and independent, noninjecting investigator–rated GAIS; subject Self-Perception of Age (SPA); subject-assessed satisfaction with and natural look of treatment; and instrument-assessed changes in static and dynamic RCL roughness, amplitude, and texture (secondary end points). Safety assessments included injection site responses (ISRs).
On Day 45, 98% of subjects rated RCL as improved or much improved (investigator rated: 95%). Subjects with same or older SPA before treatment (n = 38) perceived themselves as 2.0 and 5.5 average years younger after treatment, respectively. Day 45 mean satisfaction with and natural look of treated areas was 7.9/10 and 7.2/10, respectively. Treatment significantly improved RCL roughness, amplitude, and texture (all p < .001). Most common ISRs were hematoma (35.9%), bruising (30.2%), and irregularities/bumps (22.6%); most ISRs were mild.
VYC-17.5L effectively corrected dynamic RCL, improved instrument-assessed indicators of skin quality, and resulted in younger age perception.
*SkinConcept, Munich, Germany;
†University of Goettingen, Goettingen, Germany;
‡Medical Skincare, Sint-Truiden, Belgium;
§Garden Spa, Krakow, Poland;
║Centre Chirurgical Niforos, Lyon, France;
¶Peloton Advantage, LLC, Parsippany, New Jersey;
#Allergan plc, Marlow, United Kingdom
Address correspondence and reprint requests to: Patricia Ogilvie, MD, SkinConcept, Theatinerstraße 46, Munich 80333, Germany, or e-mail: firstname.lastname@example.org
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the full text and PDF versions of this article on the journal's Web site (www.dermatologicsurgery.org).
This study was sponsored by Allergan plc, Dublin, Ireland. Editorial assistance was provided to the authors by Peloton Advantage, an OPEN Health company, Parsippany, NJ, and was funded by Allergan plc.
P. Ogilvie, B. Fink, C. Leys, S. Lipko-Godlewska, and F. Niforos are investigators for Allergan plc, Marlow, United Kingdom. G. Kerson and M. Silberberg are employees of Allergan plc, Marlow, United Kingdom. R. Kelly provided writing services to the authors, which was funded by Allergan plc.